|
|
| | Lobradimil Basic information |
| Product Name: | Lobradimil | | Synonyms: | (Hyp3,β-(2-thienyl)-Ala5,Tyr(Me)8-(?)-Arg9)-Bradykinin Lobradimil;RMP 7;Lobradimil;(Hyp3,b-(2-thienyl)-Ala5,Tyr(Me)8-()-Arg9)-Bradykinin;H-Arg-Pro-Hyp-Gly-b-(2-thienyl)-Ala-Ser-Pro-Tyr(Me)-()-Arg-OH;LabradiMil, LabrodiMil, RMP-7, LobradiMil;(Hyp3,beta-(2-thienyl)-Ala5,Tyr(Me)8-(R)-Arg9)-Bradykinin;H-Arg-Pro-Hyp-Gly-b-(2-thienyl)-Ala-Ser-Pro-Tyr(Me)-psi(CH2NH)Arg-OH | | CAS: | 159768-75-9 | | MF: | C49H75N15O12S | | MW: | 1098.29 | | EINECS: | | | Product Categories: | | | Mol File: | 159768-75-9.mol |  |
| | Lobradimil Chemical Properties |
| density | 1.53 | | pka | 2.34±0.24(Predicted) | | form | Solid | | color | White to off-white |
| | Lobradimil Usage And Synthesis |
| Uses | Adjuvant;
receptor-mediated permeabiliser. | | in vivo | Lobradimil (2.5-mg/kg bolus plus 10 mg/kg/h for 90 minutes) increases brain tumor permeability and shows hypotensive effects in RG2 glioma cells-implanted rats[2].
| Animal Model: | RG2 glioma cells-implanted rats[2] | | Dosage: | 1.5-18 μg/kg | | Administration: | i.v. infusion, 0.05 mL/min for 15min | | Result: | Increased Carboplatin (HY-17393) uptake (up to 80%) into brain tumors in a dose-dependent manner. |
| | IC 50 | Bradykinin B2 Receptor (B2R): 0.54 nM (Ki) |
| | Lobradimil Preparation Products And Raw materials |
|